Pain drug developer Latigo rises post-upsized IPO (LTGO:NASDAQ)
· seekingalpha.com
Latigo Biotherapeutics (LTGO) stock surges after the company priced an upsized initial public offering of 19.2M shares at $18 each. Read more here.
Latigo Biotherapeutics (LTGO), a clinical-stage biopharma focused on developing non-opioid pain medicines, rose sharply on its first day of trading after an ups...